Leap Investments’s Avadel Pharmaceuticals AVDL Stock Holding History

Leap Investments’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-43,481	Closed	-$328K	–	368
2019 Q4	$328K	Buy	+43,481	New	+$230K	0.15%	227

Other funds holding AVDL

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Leap Investments's AVDL Position: Q1 2020 in Review

Leap Investments sold out of Avadel Pharmaceuticals (AVDL) in Q1 2020, closing a stake of 43,481 shares — an estimated $328K sold.

Leap Investments first reported a position in AVDL in Q4 2019 and held it in 1 quarter. The position peaked at $328K in Q4 2019. 56 funds tracked by Wall St. Rank hold AVDL as of Q1 2020.

Leap Investments reported no remaining Avadel Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Leap Investments sold 43,481 Avadel Pharmaceuticals shares in Q1 2020, an estimated $328K.
Leap Investments first reported a position in Avadel Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Leap Investments's Avadel Pharmaceuticals position peaked at $328K in Q4 2019.
56 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.